Sichuan Kelun-Biotech Biopharmaceutical (HKG:6990) First Half 2025 Results

Key Financial Results

• Revenue: CN¥950.4m (down 31% from 1H 2024).
• Net loss: CN¥145.2m (down by 147% from CN¥310.2m profit in 1H 2024).
• CN¥0.64 loss per share (down from CN¥1.41 profit in 1H 2024).

This technology could replace computers: discover the 20 stocks are working to make quantum computing a reality.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Sichuan Kelun-Biotech Biopharmaceutical EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 12%. Earnings per share (EPS) exceeded analyst estimates by 23%.

Looking ahead, revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 3.0% from a week ago.

Balance Sheet Analysis

While earnings are important, another area to consider is the balance sheet. See our latest analysis on Sichuan Kelun-Biotech Biopharmaceutical's balance sheet health.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.